SLC5A5 and ovarian carcinoma: Additionally, the Mayo Clinic performed a phase I/II trial in order to identify the side effects as well as the optimal dose of MSCs transfected with oncolytic measles virus encoding NIS (MV-NIS) in the ovarian cancer.